The AHA and American Society of Health-System Pharmacists today urged the Food and Drug Administration to take appropriate enforcement action to protect patients from a payer-mandated drug distribution model known as “white bagging.” 

Under the white bagging model, commercial health insurers require that patient medications be distributed through a narrow network of specialty pharmacies, often affiliated with the payer. Providers are then required to receive, store and administer the medications without ever taking ownership of the product or having adequate line of sight into the origin or chain of custody of each specific medication it receives, potentially jeopardizing patient safety and limiting the ability of providers to make critical care decisions for their patients. 

“White bagging has surged in frequency over the past decade, creating what amounts to a shadow inventory that hospitals and health systems do not legally own and which exists largely outside of the [Drug Supply Chain Security Act’s] track and trace requirements,” jeopardizing patient safety and exacerbating supply chain security challenges, the organizations said.
 

Related News Articles

Headline
The Senate Nov. 9 took a critical first step toward ending the government shutdown as seven Democrats and Sen. Angus King, I-Maine, joined Republicans to…
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…
Headline
There is still no clear end in sight to the government shutdown as today marks day 30 and is approaching the 35-day record that occurred in 2018-2019. Some…
Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Chairperson's File
Public
This week brings the fourth week of the federal government shutdown as Congress has yet to pass legislation to fund the government. This shutdown is a bit…
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…